Immunoregulation analysis by Propagermanium in human

Immunoregulation analysis by Propagermanium in human - PG immunoregulation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030952

Enrollment

Registered

2022-03-31

Start date

2017-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Propagermanium 30 mg/day, consecutively for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteer

Exclusion criteria

Exclusion criteria: Cancer Acute infection

Design outcomes

Primary

Measure	Time frame
Immune cell analysis (pre, 4weeks medication, drug withdrawal 4weeks)	—

Secondary

Measure	Time frame
Adverse effect (pre, 4weeks medication, drug withdrawal 4weeks), Lymph cell activation (in vitro assay)	—

Countries

Japan

Contacts

Public ContactShojiro Kikuchi

Hyogo College of Medicine Institute for Advanced Medical Sciences

skikuchi@hyo-med.ac.jp0798-45-6229

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026